## **CLAIMS**

- 1. Tamsulosin hydrochloride, ((R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino) propyl)-2-methoxybenzenesulphonamide) hydrochloride, in the amorphous form.
- 2. Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the DSC thermogram thereof exhibits an exothermic peak at about 100 °C.
- 3. Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the IR spectrum thereof exhibits a band at about 3449 cm<sup>-1</sup>.
- 4. Tamsulosin hydrochloride in the amorphous form according to claim 3 characterised in that the IR spectrum thereof exhibits the bands substantially as shown in Table 1.
- 5. Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the X-ray powder diffractogram thereof exhibits the absence of discrete diffractions which are characteristic of crystalline forms.
- 6. A process for the preparation of the amorphous form of tamsulosin hydrochloride characterised in that it comprises lyophilization of a solution of tamsulosin hydrochloride.
- 7. The process for the preparation of amorphous tamsulosin hydrochloride according to claim 6 wherein said solution of tamsulosin hydrochloride is aqueous solution.
- 8. A process for the preparation of the amorphous form of tamsulosin hydrochloride characterised in that it comprises spray-drying of a solution of tamsulosin hydrochloride.
- 9. The process for the preparation of amorphous tamsulosin hydrochloride according to claim 8 wherein said solution of tamsulosin hydrochloride is aqueous solution.

- 10. A pharmaceutical formulation comprising tamsulosin hydrochloride and one or more pharmaceutically acceptable excipients characterised in that it comprises tamsulosin hydrochloride in the amorphous form.
- 11. A pharmaceutical formulation comprising tamsulosin hydrochloride characterised in that said tamsulosin hydrochloride is prepared by the processes according to claims 6 to 9.
- 12. A method of preparing a pharmaceutical formulation of tamsulosin hydrochloride in the amorphous form comprising combining an amount of tamsulosin hydrochloride in the amorphous form with pharmaceutically acceptable excipients.
- 13. Use of tamsulosin hydrochloride in the amorphous form for the preparation of a pharmaceutical formulation together with pharmaceutically acceptable excipients.
- 14. Use of tamsulosin hydrochloride in the amorphous form for the preparation of a medicament for the treatment of benign prostatic hyperplasia.
- 15. A method of treating benign prostatic hyperplasia which comprises administering a therapeutically effective amount of amorphous tamsulosin hydrochloride in conjunction with a pharmaceutically acceptable diluent or carrier.